Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Myocet (non-pegylated liposomal doxorubicin)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Sopherion, Teva

Drug class:

Topoisomerase II inhibitor

Related drugs:

‹

›

No biomarker	Breast Cancer	No biomarker	Breast Cancer	non-pegylated liposomal doxorubicin Sensitive: A1 - Approval non-pegylated liposomal doxorubicin Sensitive : A1	non-pegylated liposomal doxorubicin Sensitive: A1 - Approval non-pegylated liposomal doxorubicin Sensitive : A1
HRD	Triple Negative Breast Cancer	HRD	Triple Negative Breast Cancer	carboplatin + paclitaxel + non-pegylated liposomal doxorubicin Sensitive: C3 – Early Trials carboplatin + paclitaxel + non-pegylated liposomal doxorubicin Sensitive : C3	carboplatin + paclitaxel + non-pegylated liposomal doxorubicin Sensitive: C3 – Early Trials carboplatin + paclitaxel + non-pegylated liposomal doxorubicin Sensitive : C3
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	cyclophosphamide + non-pegylated liposomal doxorubicin Sensitive: C3 – Early Trials cyclophosphamide + non-pegylated liposomal doxorubicin Sensitive : C3	cyclophosphamide + non-pegylated liposomal doxorubicin Sensitive: C3 – Early Trials cyclophosphamide + non-pegylated liposomal doxorubicin Sensitive : C3